| [1] |
Nakamura S, Matsumoto T. Treatment strategy for gastric mucosa-associated lymphoid tissue lymphoma[J]. Gastroenterol Clin North Am, 2015, 44(3): 649-660.
doi: 10.1016/j.gtc.2015.05.012
URL
|
| [2] |
Raderer M, Kiesewetter B, Ferreri AJM. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)[J]. CA Cancer J Clin, 2016, 66(2): 153-171.
|
| [3] |
Bracci PM, Benavente Y, Turner JJ, et al. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: The interLymph non-hodgkin lymphoma subtypes project[J]. J Natl Cancer Inst Monogr, 2014, 2014(48): 52-65.
doi: 10.1093/jncimonographs/lgu011
URL
|
| [4] |
Borie R, Wislez M, Antoine M, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma revisited[J]. Eur Respir J, 2016, 47(4): 1244-1260.
doi: 10.1183/13993003.01701-2015
pmid: 26797028
|
| [5] |
Hollie N, Asakrah S. MALT lymphoma of the colon: A clinicopathological review[J]. J Clin Pathol, 2020, 73(7): 378-383.
doi: 10.1136/jclinpath-2019-206377
pmid: 32034054
|
| [6] |
Lyapichev KA, Medeiros LJ, Ivashkevich Y, et al. MALT lymphoma of the tongue: An unusual site that may present a diagnostic challenge[J]. Ann Diagn Pathol, 2022, 56: 151841.
|
| [7] |
Iversen L, Eriksen PRG, Andreasen S, et al. Lymphoma of the sublingual gland: Clinical, morphological, histopathological, and genetic characterization[J]. Front Surg, 2020, 7: 581105.
|
| [8] |
高淇铭, 玄云泽. 唾液腺黏膜相关淋巴组织淋巴瘤的研究进展[J]. 吉林医学, 2023, 44(5): 1361-1363.
|
| [9] |
Lasica M, Anderson MA, Boussioutas A, et al. Marginal zone lymphomas: A consensus practice statement from the australasian lymphoma alliance[J]. Intern Med J, 2024, 54(6): 1017-1030.
doi: 10.1111/imj.16390
pmid: 38881453
|
| [10] |
Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of non-Hodgkin's lymphoma[J]. Med Sci, 2021, 9(1): 5.
|
| [11] |
Baldini C, Fulvio G, La Rocca G, et al. Update on the pathophysiology and treatment of primary Sjögren syndrome[J]. Nat Rev Rheumatol, 2024, 20(8): 473-491.
doi: 10.1038/s41584-024-01135-3
pmid: 38982205
|
| [12] |
Stefanski AL, Tomiak C, Pleyer U, et al. The diagnosis and treatment of sjögren's syndrome[J]. Dtsch Arztebl Int, 2017, 114(20): 354-361.
|
| [13] |
Tesher MS, Esteban Y, Henderson TO, et al. Mucosal-associated lymphoid tissue (MALT) lymphoma in association with pediatric primary sjogren syndrome: 2 cases and review[J]. J Pediatr Hematol Oncol, 2019, 41(5): 413-416.
doi: 10.1097/MPH.0000000000001321
pmid: 30371536
|
| [14] |
Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome[J]. Nat Rev Dis Primers, 2016, 2: 16047.
|
| [15] |
Verstappen GM, Pringle S, Bootsma H, et al. Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis[J]. Nat Rev Rheumatol, 2021, 17(6): 333-348.
doi: 10.1038/s41584-021-00605-2
|
| [16] |
Tsai AG, Lu ZF, Lieber MR. The t(14; 18)(q32; q21)/IGH-MALT1 translocation in MALT lymphomas is a CpG-type translocation, but the t(11; 18)(q21; q21)/API2-MALT1 translocation in MALT lymphomas is not[J]. Blood, 2010, 115(17): 3640-3641.
doi: 10.1182/blood-2010-01-265157
URL
|
| [17] |
Du MQ. MALT lymphoma: A paradigm of NF-κB dysregulation[J]. Semin Cancer Biol, 2016, 39: 49-60.
doi: 10.1016/j.semcancer.2016.07.003
URL
|
| [18] |
Isaacson PG, Du MQ. MALT lymphoma: From morphology to molecules[J]. Nat Rev Cancer, 2004, 4(8): 644-653.
doi: 10.1038/nrc1409
pmid: 15286744
|
| [19] |
陈青, 杨含金, 滕晓东, 等. 黏膜相关淋巴组织结外边缘区淋巴瘤171例临床病理与预后分析[J]. 临床与实验病理学杂志, 2020, 36(11): 1301-1306.
|
| [20] |
Win KT, Hsieh YC, Wu HC, et al. Nodal low-grade B-cell lymphoma co-expressing CD5 and CD10 but not CD23, IRTA1, or cyclin D1: The diagnostic challenge of a splenic marginal zone lymphoma[J]. Diagnostics, 2024, 14(6): 640.
doi: 10.3390/diagnostics14060640
URL
|
| [21] |
黄文娟, 王莉, 黄瑛, 等. 苯达莫司汀联合利妥昔单抗治疗惰性B细胞非霍奇金淋巴瘤的效果[J]. 中国医药科学, 2023, 13(11): 116-119.
|
| [22] |
Chen YH, Wang XY, Jin X, et al. Rituximab therapy for primary sjögren's syndrome[J]. Front Pharmacol, 2021, 12: 731122.
|
| [23] |
Delli K, Haacke EA, Kroese FGM, et al. Towards personalised treatment in primary Sjögren's syndrome: Baseline parotid histopathology predicts responsiveness to rituximab treatment[J]. Ann Rheum Dis, 2016, 75(11): 1933-1938.
doi: 10.1136/annrheumdis-2015-208304
pmid: 26757748
|
| [24] |
Alderuccio JP, Reis IM, Habermann TM, et al. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma[J]. Am J Hematol, 2022, 97(12): 1529-1537.
doi: 10.1002/ajh.26715
pmid: 36057138
|